Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study of AK104 (Anti-PD1/CTLA4 Bispecific Antibody) in Combination With Etoposide and Carboplatin Plus Low-dose Radiotherapy (LDRT) for the First-line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT06477523 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT06477523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06477523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study of AK104 (Anti-PD1/CTLA4 Bispecific Antibody) in Combination With Etoposide and Carboplatin Plus Low-dose Radiotherapy (LDRT) for the First-line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Lead sponsor
Sichuan University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 16, 2024
Completion date
December 31, 2027
Enrollment
57 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sclc, extensive stage